The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

Jennifer McNeill claimed she visited her GP and A&E several times, but was told it was muscular. A mum who struggled to lift ...

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

including Pfizer's Talzenna (talazoparib), which was approved in February for HER2-negative breast cancer "using the same process as the evaluation of Enhertu for advanced HER2-low breast cancer." ...

The fight to lower prescription drug prices is hitting African Americans especially hard. A recent report by Patients ...

A recent report by Patients for Affordable Drugs reveals that pharmaceutical companies have increased prices on more than ...

Trial results suggested the antibody-drug conjugate may be a treatment option for patients with HER2 metastatic breast cancer ...

With Breast Cancer Awareness Month beginning this week men and women are coming together to confront a disease impacting so ...

PEOPLE and Verywell Health teamed up to bring you the latest insight into breast cancer treatments and outcomes, as well as ...

Best friends Melissa Berry and Deltra launched their podcast series 'Empowered Intimacy: Getting Your Sexy Back After Breast ...

Black women are more likely to be affected by breast cancer compared to their counterparts. A new FDA ruling can improve ...